U.S. pharmaceuticals company Eli Lilly plans to build a new plant in western Germany, sources close to the matter told…
…
MAINZ/ALZEY (dpa-AFX) - Der US-Pharmakonzern Eli Lilly plant einem Bericht zufolge einen Produktionsstandort in Rheinland-Pfalz.…
Despite little prescriber differentiation between the JAKs, including satisfaction and manufacturer perceptions, Olumiant is projected to maintain a significant market…
Novo Nordisk (NYSE:NVO) presented the full results from its SELECT cardiovascular trial at an American Heart Association (AHA) meeting on…
Eli Lilly and Co (NYSE:LLY)s experimental therapy lepodisiran reduced the harmful risk factor for lipoprotein (a) by up to 94%…
Prior to launch, prescribers estimate that TNF inhibitors are likely to bear the greatest brunt of increased adoption of the…
Here are Mondays biggest calls on Wall Street.…
Analysts said upcoming data on Pfizers obesity pill, danuglipron, will be crucial to how competitive the company can be against…
Both of these companies are reporting positive news for their competing weight-loss drugs, but which is the better stock to…
…
Drug, biotech companies are likely to see significant innovation. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), Novo Nordisk (NVO),…
…
The findings could expand use of Wegovy and help Novo maintain its lead over Eli Lilly, whose competing weight-loss drug…
"The incumbent almost always wins," Jim Cramer said this week.…
Also: Bad and good results this earnings season, new tax rules, stock picks and how you too can be a…
With Eli Lilly’s Zepbound set to enter the fray, companies are flooded with weight-loss drug questions…
If management has its way, Eli Lillys earnings and share price will be way up.…
…
"You really have to dig into individual companies and sectors," says the T. Rowe Price strategist, naming some of his…
…
…
Eli Lilly, Novo Nordisk drop as UnitedHealth lowers Insulin costs…
This competition is leading to a lot of serious innovation.…
Eli Lilly: still seeking UK approval on pen for weight-loss drug…
One of this year’s hottest stocks is on pace for its worst day of the year.
Eli Lilly shares are down…
…
Pfizer, Eli Lilly, General Motors and Tesla have been highlighted in this Earnings Trends article.…
Howie and Harlan are joined by the New Yorkers Dhruv Khullar to talk about his life as a clinician, researcher,…
Shares of Eli Lilly jumped Wednesday after the U.S. gave the green light for the companys blockbuster GLP-1 drug to…
Eli Lilly gets FDA approval for new obesity drug…
Zepbound helped patients lose up to 48 pounds on average in clinical trials.…
…
The obesity approval further establishes Eli Lilly as a formidable competitor to Novo Nordisk in the budding weight loss drug…
Aggressive investments in growth have left the pharma giant with smaller profits this year.…
Eli Lilly was a strong performer Monday, while energy plays were among the indexs biggest winners and losers.…
…
…
…
An der US-amerikanischen Börse liegt die Eli Lilly-Aktie derzeit im Plus. Das Papier kostete zuletzt 590,69 US-Dollar. Im US-amerikanischen Wertpapierhandel…
The answer is relatively clear.…
Lillys Mounjaro is gaining ground on Novo Nordisks Ozempic.…
Lillys Mounjaro is gaining ground on Novo Nordisks Ozempic.…
Eli Lilly (LLY) posted robust third-quarter 2023 earnings results, beating estimates on both the top and bottom lines. Its Mounjaro…
The case for owning Eli Lilly got stronger Thursday, as diabetes drug Mounjaro crossed $1 billion in quarterly sales for…
LLY earnings call for the period ending September 30, 2023.…
These are the stocks posting the largest moves in midday trading.…
The remarks suggest that Eli Lillys initial efforts to expand manufacturing capacity for Mounjaro are paying off as demand for…
Eli Lilly and Co (NYSE:LLY) reported impressive third-quarter revenue as its diabetes drug Mounjaro exceeded sales expectations. The blockbuster drug...…
INDIANAPOLIS (dpa-AFX) - Der Pharmakonzern Eli Lilly and Company wächst weiter rasant. Auch im vergangenen…